AUTHOR=Grubelnik Gašper , Boštjančič Emanuela , Aničin Aleksandar , Dovšak Tadej , Zidar Nina 

TITLE=MicroRNAs and Long Non-Coding RNAs as Regulators of NANOG Expression in the Development of Oral Squamous Cell Carcinoma

JOURNAL=Frontiers in Oncology

VOLUME=10

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.579053

DOI=10.3389/fonc.2020.579053

ISSN=2234-943X

ABSTRACT=<p>NANOG is a stem cell transcription factor that is believed to play an important role in the development of oral squamous cell carcinoma (OSCC), but there is limited data regarding the role of long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) in the regulation of NANOG expression. We therefore analyzed expression of NANOG, NANOG-regulating miRNAs and lncRNAs in OSCC cancerogenesis, using oral biopsy samples from 66 patients including normal mucosa, dysplasia, and OSCC. Expression analysis of <italic>NANOG</italic>, <italic>miR-34a</italic>, <italic>miR-145</italic>, <italic>RoR</italic>, <italic>SNHG1</italic>, <italic>AB209630</italic>, and <italic>TP53</italic> was performed using qPCR and immunohistochemistry for NANOG protein detection. NANOG protein showed no staining in normal mucosa, very weak in low-grade dysplasia, and strong staining in high-grade dysplasia and OSCC. <italic>NANOG</italic>, <italic>miR-145</italic>, <italic>RoR</italic>, and <italic>SNHG1</italic> showed up-regulation, <italic>TP53</italic> and <italic>miR-34a</italic> showed down-regulation, and <italic>AB209630</italic> showed variable expression during cancerogenesis. NANOG mRNA was up-regulated early in cancerogenesis, before strong protein expression can be detected. <italic>NANOG</italic> was in correlation with <italic>miR-145</italic> and <italic>RoR</italic>. Our results suggest that miRNAs and lncRNAs, particularly <italic>miR-145</italic> and <italic>RoR</italic>, might be important post-transcription regulatory mechanisms of NANOG in OSCC cancerogenesis. Furthermore, NANOG protein detection has a diagnostic potential for oral high-grade dysplasia, distinguishing it from low-grade dysplasia and non-neoplastic reactive lesions.</p>